Recombinant bacillus Calmette-Guérin as a potential vector for preventive HIV type 1 vaccines.
AIDS Res Hum Retroviruses
; 16(2): 91-8, 2000 Jan 20.
Article
en En
| MEDLINE
| ID: mdl-10659047
ABSTRACT
In August 1997, the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) convened an expert working group to discuss current strategies for the development of HIV type 1 vaccines. Based on the recent findings of investigators from Japan's National Institute of Infectious Diseases (NIID) in Tokyo using recombinant bacillus Calmette-Guérin (rBCG) as a potential vectored vaccine for HIV, a recommendation was made that further work in this area is a priority. As a result, the working group reconvened in September 1998 to discuss the progress to date with this vaccine approach, as well as areas of related research to assess the feasibility of a BCG-vectored HIV vaccine. This report summarizes the discussions addressing the available scientific data on the potential use of rBCG as a vector for preventive HIV vaccines, the work necessary to move such candidate vaccines into Phase 1 clinical trials, and recommendations targeted at facilitating the long-term development of rBCG-vectored HIV vaccines.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Vacuna BCG
/
Vacunas Sintéticas
/
Infecciones por VIH
/
VIH-1
/
Vacunas contra el SIDA
Tipo de estudio:
Guideline
Límite:
Animals
/
Humans
Idioma:
En
Revista:
AIDS Res Hum Retroviruses
Asunto de la revista:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Año:
2000
Tipo del documento:
Article
País de afiliación:
Estados Unidos